menu
    • menu

    Company profile for Emalex Bioscience

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Emalex is committed to addressing unmet medical needs by developing novel treatments for central nervous system movement disorders and fluency disorders. We partner with patient advocacy organizations to raise awareness of these disorders and support their education outreach and communication efforts.Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurol...
    Emalex is committed to addressing unmet medical needs by developing novel treatments for central nervous system movement disorders and fluency disorders. We partner with patient advocacy organizations to raise awareness of these disorders and support their education outreach and communication efforts.Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Emalex BioscienceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    330 N. Wabash, Suite 3500, Chicago, IL 60611
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://emalexbiosciences.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/emalex-biosciences/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Emalex Gets FDA OK for Tourette Drug Expanded Access Program
    Emalex Gets FDA OK for Tourette Drug Expanded Access Program

    08 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251007679744/en/Emalex-Biosciences-Expanded-Access-Program-for-Investigational-Tourette-Syndrome-Drug-Receives-FDA-Authorization

    BUSINESSWIRE
    08 Oct 2025
    Share Share
    Emalex eyes potential Tourette approval after phase 3 win
    Emalex eyes potential Tourette approval after phase 3 win

    26 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/emalex-dopamine-blocker-stops-tourette-syndrome-relapse-phase-3-win

    FIERCE BIOTECH
    26 Feb 2025
    Share Share
    Emalex’s Lead Drug Hits Goals In Ph 3 Tourette Study
    Emalex’s Lead Drug Hits Goals In Ph 3 Tourette Study

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225561932/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share
    Emalex Releases Results of 12-Month Open-Label Extension Study
    Emalex Releases Results of 12-Month Open-Label Extension Study

    05 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231004005988/en

    BUSINESSWIRE
    05 Oct 2023
    Share Share
    Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam
    Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam

    01 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/emalex-biosciences-announces-first-patient-dosed-in-phase-3-trial-of-ecopipam-for-tourette-syndrome-301759554.html

    PR NEWSWIRE
    01 Mar 2023
    Share Share
    Emalex Biosciences reports data from Tourette syndrome therapy trial
    Emalex Biosciences reports data from Tourette syndrome therapy trial

    12 Jan 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/emalex-biosciences-tourette-syndrome/

    CLINICAL TRIALS ARENA
    12 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search